AZ-Pfizer side effects: Partnership crossover casualties coming soon?
This article was originally published in Scrip
As the Pfizer, AstraZeneca megamerger circus continues following meetings between UK government committees and both companies' chiefs executives (scripintelligence.com, 15 May 2014), Scrip has been investigating possible repercussions a takeover could have on the giant drug makers' smaller pharma and biotech partners.
You may also be interested in...
For In Vivo's 16th annual Deals of the Year contest, we selected 12 nominees in three categories – Top Alliance, Top Financing and Top M&A. The polls are closed, and it is time to reveal the winners.
The last quarter of 2023 was an exciting one for the cell and gene therapy sector – with the first-ever approval for a CRISPR-based therapeutic in the US and an increase in Phase III trials in the overall CGT pipeline.
Non-executive chair Peter Bains and Owain Millington, vice president of immunology and head of preclinical, discuss ILC Therapeutics’ platform technology, financing plans as well as the pros and cons of running a startup biotech in the UK.